ClinicalTrials.gg
CompletedNCT05161806Updated Nov 18, 2022Results posted

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe

A Phase 3 interventional study of SOK583A1 (40 mg/mL) and Prefilled Syringe (PFS) in Neovascular Age-related Macular Degeneration (nAMD), sponsored by Sandoz. Completed at 3 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2022-11-18.

Sponsored by Sandoz (formerly part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.

Enrollment
52nd of 66
30 · median 55
Started
2022
with 3 others
Phase 3
18 of 66
1 open now
Registered
51st of 66
by date
Lead sponsor
3 of 66
Sandoz

Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 52nd largest by enrollment, is one of 4 that started in 2022, is one of 18 in phase 3, and was the 51st registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing aflibercept in Macular Degeneration, or all of them as a file.
02

Study summary

This was an open-label, single arm, multicenter, Phase IIIb study in subjects with (wet) nAMD, eligible for IVT aflibercept treatment.

Read the detailed description

This was an open-label, single arm, multicenter, Phase IIIb study in subjects with nAMD, eligible for Intravitreal (IVT) aflibercept treatment.

Screening and Baseline could be performed on the same day.

Subjects with nAMD received a single dose of study treatment (2 mg SOK583 in 0.05 mL) in line with the Eylea US PI, which recommends a dose of 2 mg aflibercept (0.05 mL) administered by IVT injection. Only subjects already under IVT Eylea treatment and hence familiar with the IVT procedure were eligible for the study. Administration of the study treatment was embedded into their individual dosing schedule.

Demonstration of the safe use of the PFS containing SOK583A1 was based on the performance of at least 3 different ophthalmologist teams.

Follow-up visits were performed on-site on Day 8 (±2 days) and on Day 31 (+4 days - end of study visit). Subjects participated for 30 to 34 days in the study including Baseline and treatment on Day 1 (Screening and Baseline could be performed on the same day) and the last safety follow-up on Day 31 (a time window of plus 4 days was allowed for the last safety follow-up).

03

Conditions studied

  • Neovascular Age-related Macular Degeneration (nAMD)

Keywords

  • Open label study,
  • intravitreal injection,
  • biosimilar,
  • aflibercept,
  • PFS
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects ≥ 50 years of age at baseline
  • Subjects diagnosed with nAMD (uni- or bilateral)
  • Subjects already under IVT Eylea treatment (last injection of the induction period or maintenance phase)

Exclusion criteria

Exclusion Criteria:

  • Active or recent (within 4 weeks) intraocular inflammation (grade trace or above) in the study eye at baseline, which is of clinical significance according to the investigator's judgment, such as active infections of the anterior segment; this includes conjunctivitis (except mild blepharitis), keratitis, scleritis, idiopathic or associated uveitis or endophthalmitis
  • Any uncontrolled ocular hypertension or glaucoma in the study eye (defined as intraocular pressure (IOP) ≥ 26 mmHg, despite treatment with anti-glaucomatous medication)
  • History of a medical, ocular or non-ocular condition, that in the judgment of the investigator, would preclude a safe administration of product
  • Visual Acuity Score (VAS) worse than 20/200 on a Snellen chart, the generally accepted level of legal blindness
  • Receipt of any systemic anti-VEGF within the last 6 months prior to enrollment
  • Uncontrolled hypertension (defined as a systolic value ≥ 160 mmHg or diastolic value ≥ 100 mmHg at Screening)
  • Subjects who do not comply with the local COVID-19 regulations of the study site
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    SOK583A1 (40 mg/mL)

    participants received a single dose of 2 mg SOK583 in 0.05 mL (40 mg/mL) and completed the study

    Drug: SOK583A1 (40 mg/mL) · Device: Prefilled Syringe (PFS)

Interventions

  • DrugSOK583A1 (40 mg/mL)

    Drug page: Aflibercept

    SOK583A1 provided in a Prefilled Syringe (PFS), which includes 2 mg aflibercept in 0.05 mL for IVT administration

    Also known as: aflibercept

  • DevicePrefilled Syringe (PFS)

    Prefilled Syringe (PFS)

06

What researchers measure

Primary outcomes

  1. Number of Participants With Ocular Treatment Emergent Adverse Events

    Number of participants with ocular treatment emergent adverse events were reported.

    Time frame: throughout the study, approximately 31 days

  2. Number of Participants With Non-ocular Treatment Emergent Adverse Events

    Number of participants with non ocular Treatment emergent adverse events were reported.

    Time frame: throughout the study, approximately 31 days

07

Results

Posted Nov 18, 2022

Participant flow

Study was conducted in 3 study sites in the US. All 3 sites screened and treated participants.

Participant flow — Overall Study
MilestoneSOK583A1 (40 mg/mL)
Started30
Full analysis set (fas)30
Completed30
Not completed0

Outcome measures

PrimaryNumber of Participants With Ocular Treatment Emergent Adverse Events

Number of participants with ocular treatment emergent adverse events were reported.

Time frame:
throughout the study, approximately 31 days
Reported as:
Count of participants · Participants
Number of Participants With Ocular Treatment Emergent Adverse Events
ParticipantsSOK583A1 (40 mg/mL)
Number of Participants With Ocular Treatment Emergent Adverse Events2
PrimaryNumber of Participants With Non-ocular Treatment Emergent Adverse Events

Number of participants with non ocular Treatment emergent adverse events were reported.

Time frame:
throughout the study, approximately 31 days
Reported as:
Count of participants · Participants
Number of Participants With Non-ocular Treatment Emergent Adverse Events
ParticipantsSOK583A1 (40 mg/mL)
Number of Participants With Non-ocular Treatment Emergent Adverse Events1

Adverse events

Collected over Adverse events were collected throughout the study i.e. approximately 31 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SOK583A1 (40 mg/mL)0/30 (0%)0/30 (0%)3/30 (10%)
Most frequent other events
Most frequent other events
EventSOK583A1 (40 mg/mL)
Foreign body sensation in eyesEye disorders1/30
Intraocular pressure increasedInvestigations1/30
HypertensionVascular disorders1/30
Ocular discomfortEye disorders1/30

Baseline characteristics

Age, Continuous
Age, Continuous(Years)SOK583A1 (40 mg/mL)
Mean79.4 ± 7.41
Sex: Female, Male
Sex: Female, Male(Participants)SOK583A1 (40 mg/mL)
Female19
Male11
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SOK583A1 (40 mg/mL)
White30
08

Study locations

3 sites
  • Sandoz Investigational Site
    Marietta, Georgia 30060, United States
  • Sandoz Investigational Site
    Oak Forest, Illinois 60452, United States
  • Sandoz Investigational Site
    Liverpool, New York 13088, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in May 2022, 1 month.

Results were first posted in Nov 2022, 6 months after primary completion.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 1 month is below that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2021
First posted
Dec 17, 2021
StartActual
Mar 11, 2022
Primary completionActual
May 4, 2022
CompletionActual
May 4, 2022
Results first posted
Nov 18, 2022
Last update
Nov 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05161806
Lead sponsor
Sandoz
Responsible party
Sponsor
First posted
Dec 17, 2021
Start date
Mar 11, 2022
Primary completion
May 4, 2022
Completion
May 4, 2022
Results posted
Nov 18, 2022
Last update
Nov 18, 2022

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion